Encorafenib Drug Asset Due Diligence Report 2026

This Encorafenib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

108

Registered trials

158

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Encorafenib can convert its Small molecule drug profile and BRAF V600E biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Encorafenib (query alias: encorafenib)
Modality / target	Small molecule drug; BRAF V600E; BRAF V600E inhibitors
Highest global status	Approved
Originator	Array BioPharma, Inc.
Active developers	Pfizer Inc., Pierre Fabre Médicament SAS, Pierre Fabre Medicament Information

The MCP disease footprint includes Colorectal Cancer, Melanoma, Metastatic Colorectal Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07318389	Early Phase 1	Not yet recruiting	100	safety and adverse events (AEs)
JPRN-jRCT1031260160	Not Applicable	募集中	130	治療状況 ‧ENC+BIN併⽤療法投与開始時の患者情報（年齢、性別、組織型、遠隔転移の有無、転移部位等） ‧ ENC+BIN併⽤療法の治療状況（投与期間、継続/減量/休薬/中⽌率、投与量、休薬/中⽌理由等）有効性・RECIST ver1.1に準拠した主治医評価による全奏効率安全性・ENC+BIN併⽤療法投与開始から最終投与後28日以内の有害事象の発現割合
CTR20261861	Not Applicable	进行中（招募完成）	48	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER

Phase 3; n=841; evaluation: not stated. Reported fields: -; SLI: Number of Participants With Dose Limiting Toxicity (DLTs) = 0 Participants ; -

Overall survival benefit of doublet versus triplet BRAF inhibitor–based therapy: Insights from the BEETS study (JACCRO CC-18).

Not Applicable; n=162; evaluation: Positive. Reported fields: mOS(RAD51C High) = 12.9 month ; mOS(RAD51C High) = 28.2 month

A multicenter phase II trial of encorafenib, binimetinib, and cetuximab for early relapsed stage II/III BRAF<sup>V600E</sup>-mutated colorectal cancer: TRESBIEN trial (OGSG 2101).

Phase 2; n=25; evaluation: Positive. Reported fields: ORR = 62.5 % ( 40.6 - 81.2)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Encorafenib addresses Colorectal Cancer, Melanoma, Metastatic Colorectal Carcinoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 10 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-11-26	皮尔法伯与国药控股达成战略合作共拓中国肿瘤治疗新格局	Approved	Financial terms not disclosed
2022-11-30	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination	Approved	Financial terms not disclosed
2022-09-13	Strata Oncology Announces Expansion of Clinical Collaboration with Pfizer for Strata PATH Trial into Early-Stage Cancer	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Formulations comprising crystalline nanosized encorafenib”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO